Boehringer, Zealand’s obesity data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 28 April, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

presented by Glob­al part­ner­ing be­fore the term sheet: de-risk­ing bio­phar­ma deals from day one

news Lilly strikes second partnership this year for recombinase-based gene editing Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending Boehringer, Zealand’s obesity shot looks as good as Wegovy but weaker than Zepbound Galapagos spinout Coultreon raises $125M for new take on SIK inhibition A showdown in the clinic and the courts: Erasca and Revolution battle over RAS

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

ENDPOINTS PHARMA Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next •  Intellia's in vivo CRISPR therapy first to succeed in Phase 3 Sun Pharma to buy Organon for $11.75B in major portfolio expansion News Briefing Thermo Fisher sells microbiology biz; Ligand to buy XOMA

in case you missed it 1. Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor 2. Updated: Compass Therapeutics' stock plummets as it unveils more data from pivotal biliary tract cancer trial 3. Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi 4.